05.18.15
Novartis
1Q Revenues: $11.9 billion (-7%)
1Q Earnings: $2.3 billion (-6%)
Comments: Pharmaceutical sales were $7.1 billion in the quarter, down 9%, and included the new oncology assets acquired from GSK (sales of $0.2 billion in March), offset by the negative impact of generic competition, largely for Diovan, Exforge and Vivelle-Dot in the U.S. Growth Products, which include Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD portfolio, and Jakavi - generated $2.9 billion, up 25%. Alcon sales were $2.6 billion, down 3% in the quarter. Sandoz sales were $2.2 billion, down 3%. U.S. sales of generics and biosimilars were up 13% (cc), driven by continuing strong performance from recent launches and Fougera sales. The company gained three approvals in oncology in the quarter: Jakavi in polycythemia vera (EU), Farydak in multiple myeloma (U.S.) and Jadenu for chronic iron overload (U.S.).
1Q Revenues: $11.9 billion (-7%)
1Q Earnings: $2.3 billion (-6%)
Comments: Pharmaceutical sales were $7.1 billion in the quarter, down 9%, and included the new oncology assets acquired from GSK (sales of $0.2 billion in March), offset by the negative impact of generic competition, largely for Diovan, Exforge and Vivelle-Dot in the U.S. Growth Products, which include Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD portfolio, and Jakavi - generated $2.9 billion, up 25%. Alcon sales were $2.6 billion, down 3% in the quarter. Sandoz sales were $2.2 billion, down 3%. U.S. sales of generics and biosimilars were up 13% (cc), driven by continuing strong performance from recent launches and Fougera sales. The company gained three approvals in oncology in the quarter: Jakavi in polycythemia vera (EU), Farydak in multiple myeloma (U.S.) and Jadenu for chronic iron overload (U.S.).